PP2B  ||| S:0 E:5 ||| NNP
and  ||| S:5 E:9 ||| CC
ERK1 ||| S:9 E:13 ||| CD
/ ||| S:13 E:14 ||| CD
2  ||| S:14 E:16 ||| CD
regulate  ||| S:16 E:25 ||| NNS
hyaluronan  ||| S:25 E:36 ||| VBP
synthesis  ||| S:36 E:46 ||| VBN
of  ||| S:46 E:49 ||| IN
HT168  ||| S:49 E:55 ||| NNP
and  ||| S:55 E:59 ||| CC
WM35  ||| S:59 E:64 ||| CD
human  ||| S:64 E:70 ||| JJ
melanoma  ||| S:70 E:79 ||| JJ
cell  ||| S:79 E:84 ||| NN
lines  ||| S:84 E:90 ||| NNS
Hyaluronan  ||| S:90 E:101 ||| NNP
( ||| S:101 E:102 ||| -LRB-
HA ||| S:102 E:104 ||| NNP
)  ||| S:104 E:106 ||| -RRB-
is  ||| S:106 E:109 ||| VBZ
the  ||| S:109 E:113 ||| DT
major  ||| S:113 E:119 ||| JJ
glycosaminoglycan  ||| S:119 E:137 ||| JJ
component  ||| S:137 E:147 ||| NN
of  ||| S:147 E:150 ||| IN
the  ||| S:150 E:154 ||| DT
extracellular  ||| S:154 E:168 ||| JJ
matrix  ||| S:168 E:175 ||| NN
in  ||| S:175 E:178 ||| IN
either  ||| S:178 E:185 ||| DT
normal  ||| S:185 E:192 ||| JJ
or  ||| S:192 E:195 ||| CC
malignant  ||| S:195 E:205 ||| JJ
tissues  ||| S:205 E:213 ||| NNS
and  ||| S:213 E:217 ||| CC
it  ||| S:217 E:220 ||| PRP
may  ||| S:220 E:224 ||| MD
affect  ||| S:224 E:231 ||| VB
proliferation ||| S:231 E:244 ||| NN
,  ||| S:244 E:246 ||| ,
motility  ||| S:246 E:255 ||| NN
and  ||| S:255 E:259 ||| CC
differentiation  ||| S:259 E:275 ||| NN
of  ||| S:275 E:278 ||| IN
various  ||| S:278 E:286 ||| JJ
cell  ||| S:286 E:291 ||| NN
types ||| S:291 E:296 ||| NNS
.  ||| S:296 E:298 ||| .
Three  ||| S:298 E:304 ||| CD
isoforms  ||| S:304 E:313 ||| NN
of  ||| S:313 E:316 ||| IN
plasma  ||| S:316 E:323 ||| FW
membrane-bound  ||| S:323 E:338 ||| FW
hyaluronan  ||| S:338 E:349 ||| FW
synthases  ||| S:349 E:359 ||| FW
( ||| S:359 E:360 ||| -LRB-
HAS  ||| S:360 E:364 ||| NNP
1 ||| S:364 E:365 ||| CD
,  ||| S:365 E:367 ||| ,
2  ||| S:367 E:369 ||| CD
and  ||| S:369 E:373 ||| CC
3 ||| S:373 E:374 ||| LS
)  ||| S:374 E:376 ||| -RRB-
secrete  ||| S:376 E:384 ||| NN
and  ||| S:384 E:388 ||| CC
simultaneously  ||| S:388 E:403 ||| RB
bind  ||| S:403 E:408 ||| JJ
pericellular  ||| S:408 E:421 ||| JJ
HA ||| S:421 E:423 ||| NNP
.  ||| S:423 E:425 ||| .
HAS  ||| S:425 E:429 ||| VBZ
enzymes  ||| S:429 E:437 ||| RB
are  ||| S:437 E:441 ||| VBP
subjects  ||| S:441 E:450 ||| NNS
of  ||| S:450 E:453 ||| IN
post-translational  ||| S:453 E:472 ||| JJ
protein  ||| S:472 E:480 ||| NN
phosphorylation  ||| S:480 E:496 ||| NNS
which  ||| S:496 E:502 ||| WDT
is  ||| S:502 E:505 ||| VBZ
believed  ||| S:505 E:514 ||| VBN
to  ||| S:514 E:517 ||| TO
regulate  ||| S:517 E:526 ||| VB
their  ||| S:526 E:532 ||| PRP$
enzymatic  ||| S:532 E:542 ||| JJ
activity ||| S:542 E:550 ||| NN
.  ||| S:550 E:552 ||| .
In  ||| S:552 E:555 ||| IN
this  ||| S:555 E:560 ||| DT
study ||| S:560 E:565 ||| NN
,  ||| S:565 E:567 ||| ,
we  ||| S:567 E:570 ||| PRP
investigated  ||| S:570 E:583 ||| VBD
the  ||| S:583 E:587 ||| DT
HA  ||| S:587 E:590 ||| NNP
homeostasis  ||| S:590 E:602 ||| NN
of  ||| S:602 E:605 ||| IN
normal  ||| S:605 E:612 ||| JJ
human  ||| S:612 E:618 ||| JJ
epidermal  ||| S:618 E:628 ||| JJ
melanocytes ||| S:628 E:639 ||| NN
,  ||| S:639 E:641 ||| ,
HT168  ||| S:641 E:647 ||| NNP
and  ||| S:647 E:651 ||| CC
WM35  ||| S:651 E:656 ||| CD
human  ||| S:656 E:662 ||| JJ
melanoma  ||| S:662 E:671 ||| JJ
cell  ||| S:671 E:676 ||| NN
lines  ||| S:676 E:682 ||| NNS
and  ||| S:682 E:686 ||| CC
melanoma  ||| S:686 E:695 ||| JJ
metastases ||| S:695 E:705 ||| NN
.  ||| S:705 E:707 ||| .
HAS2  ||| S:707 E:712 ||| NNP
and  ||| S:712 E:716 ||| CC
HAS3  ||| S:716 E:721 ||| NNP
were  ||| S:721 E:726 ||| VBD
detected  ||| S:726 E:735 ||| VBN
in  ||| S:735 E:738 ||| IN
all  ||| S:738 E:742 ||| PDT
the  ||| S:742 E:746 ||| DT
samples ||| S:746 E:753 ||| NNS
,  ||| S:753 E:755 ||| ,
while  ||| S:755 E:761 ||| IN
the  ||| S:761 E:765 ||| DT
expression  ||| S:765 E:776 ||| NN
of  ||| S:776 E:779 ||| IN
HAS1  ||| S:779 E:784 ||| NNP
was  ||| S:784 E:788 ||| VBD
not  ||| S:788 E:792 ||| RB
detectable  ||| S:792 E:803 ||| VBN
in  ||| S:803 E:806 ||| IN
any  ||| S:806 E:810 ||| DT
case ||| S:810 E:814 ||| NN
.  ||| S:814 E:816 ||| .
Malignant  ||| S:816 E:826 ||| JJ
tissue  ||| S:826 E:833 ||| NN
samples  ||| S:833 E:841 ||| NNS
and  ||| S:841 E:845 ||| CC
melanoma  ||| S:845 E:854 ||| JJ
cell  ||| S:854 E:859 ||| NN
lines  ||| S:859 E:865 ||| NNS
contained  ||| S:865 E:875 ||| VBD
extra-  ||| S:875 E:882 ||| JJ
and  ||| S:882 E:886 ||| CC
intracellular  ||| S:886 E:900 ||| JJ
HA  ||| S:900 E:903 ||| NNP
abundantly  ||| S:903 E:914 ||| NN
but  ||| S:914 E:918 ||| CC
not  ||| S:918 E:922 ||| RB
normal  ||| S:922 E:929 ||| JJ
melanocytes ||| S:929 E:940 ||| NN
.  ||| S:940 E:942 ||| .
Applying  ||| S:942 E:951 ||| NNP
HA  ||| S:951 E:954 ||| NNP
as  ||| S:954 E:957 ||| IN
a  ||| S:957 E:959 ||| DT
chemoattractant  ||| S:959 E:975 ||| NN
facilitated  ||| S:975 E:987 ||| VBD
the  ||| S:987 E:991 ||| DT
migration  ||| S:991 E:1001 ||| NN
of  ||| S:1001 E:1004 ||| IN
melanoma  ||| S:1004 E:1013 ||| JJ
cells  ||| S:1013 E:1019 ||| NNS
in  ||| S:1019 E:1022 ||| IN
Boyden  ||| S:1022 E:1029 ||| NNP
chamber ||| S:1029 E:1036 ||| NN
.  ||| S:1036 E:1038 ||| .
The  ||| S:1038 E:1042 ||| DT
amount  ||| S:1042 E:1049 ||| NN
of  ||| S:1049 E:1052 ||| IN
HA  ||| S:1052 E:1055 ||| NNP
was  ||| S:1055 E:1059 ||| VBD
reduced  ||| S:1059 E:1067 ||| VBN
upon  ||| S:1067 E:1072 ||| IN
the  ||| S:1072 E:1076 ||| DT
inhibition  ||| S:1076 E:1087 ||| NN
of  ||| S:1087 E:1090 ||| IN
calcineurin  ||| S:1090 E:1102 ||| NN
with  ||| S:1102 E:1107 ||| IN
cyclosporine  ||| S:1107 E:1120 ||| VBG
A  ||| S:1120 E:1122 ||| DT
( ||| S:1122 E:1123 ||| -LRB-
CsA ||| S:1123 E:1126 ||| NNP
) ||| S:1126 E:1127 ||| -RRB-
,  ||| S:1127 E:1129 ||| ,
while  ||| S:1129 E:1135 ||| IN
the  ||| S:1135 E:1139 ||| DT
inhibition  ||| S:1139 E:1150 ||| NN
of  ||| S:1150 E:1153 ||| IN
ERK1 ||| S:1153 E:1157 ||| CD
/ ||| S:1157 E:1158 ||| CD
2  ||| S:1158 E:1160 ||| CD
with  ||| S:1160 E:1165 ||| IN
PD098059  ||| S:1165 E:1174 ||| NNP
elevated  ||| S:1174 E:1183 ||| VBD
it  ||| S:1183 E:1186 ||| PRP
in  ||| S:1186 E:1189 ||| IN
both  ||| S:1189 E:1194 ||| DT
cell  ||| S:1194 E:1199 ||| NN
lines ||| S:1199 E:1204 ||| NNS
.  ||| S:1204 E:1206 ||| .
The  ||| S:1206 E:1210 ||| DT
signals  ||| S:1210 E:1218 ||| NNS
of  ||| S:1218 E:1221 ||| IN
Ser ||| S:1221 E:1224 ||| NNP
/ ||| S:1224 E:1225 ||| NNP
Thr  ||| S:1225 E:1229 ||| NNP
phosphoproteins  ||| S:1229 E:1245 ||| NN
at  ||| S:1245 E:1248 ||| IN
57  ||| S:1248 E:1251 ||| CD
kD  ||| S:1251 E:1254 ||| NN
were  ||| S:1254 E:1259 ||| VBD
stronger  ||| S:1259 E:1268 ||| JJR
after  ||| S:1268 E:1274 ||| IN
CsA  ||| S:1274 E:1278 ||| JJ
treatment ||| S:1278 E:1287 ||| NN
,  ||| S:1287 E:1289 ||| ,
while  ||| S:1289 E:1295 ||| IN
a  ||| S:1295 E:1297 ||| DT
markedly  ||| S:1297 E:1306 ||| RB
weaker  ||| S:1306 E:1313 ||| JJR
signal  ||| S:1313 E:1320 ||| NN
was  ||| S:1320 E:1324 ||| VBD
detected  ||| S:1324 E:1333 ||| VBN
upon  ||| S:1333 E:1338 ||| IN
inhibition  ||| S:1338 E:1349 ||| NN
of  ||| S:1349 E:1352 ||| IN
the  ||| S:1352 E:1356 ||| DT
MAPK  ||| S:1356 E:1361 ||| NNP
pathway ||| S:1361 E:1368 ||| NN
.  ||| S:1368 E:1370 ||| .
Our  ||| S:1370 E:1374 ||| PRP$
results  ||| S:1374 E:1382 ||| NNS
suggest  ||| S:1382 E:1390 ||| VBP
opposing  ||| S:1390 E:1399 ||| VBG
effects  ||| S:1399 E:1407 ||| NNS
of  ||| S:1407 E:1410 ||| IN
the  ||| S:1410 E:1414 ||| DT
two  ||| S:1414 E:1418 ||| CD
investigated  ||| S:1418 E:1431 ||| JJ
enzymes  ||| S:1431 E:1439 ||| NN
on  ||| S:1439 E:1442 ||| IN
the  ||| S:1442 E:1446 ||| DT
HA  ||| S:1446 E:1449 ||| NNP
homeostasis  ||| S:1449 E:1461 ||| NN
of  ||| S:1461 E:1464 ||| IN
melanoma  ||| S:1464 E:1473 ||| JJ
cells ||| S:1473 E:1478 ||| NNS
.  ||| S:1478 E:1480 ||| .
We  ||| S:1480 E:1483 ||| PRP
propose  ||| S:1483 E:1491 ||| VBP
that  ||| S:1491 E:1496 ||| IN
the  ||| S:1496 E:1500 ||| DT
dephosphorylation  ||| S:1500 E:1518 ||| NN
of  ||| S:1518 E:1521 ||| IN
HAS  ||| S:1521 E:1525 ||| VBZ
enzymes  ||| S:1525 E:1533 ||| VBN
targeted  ||| S:1533 E:1542 ||| VBN
by  ||| S:1542 E:1545 ||| IN
PP2B  ||| S:1545 E:1550 ||| CD
augments  ||| S:1550 E:1559 ||| JJ
HA  ||| S:1559 E:1562 ||| NNP
production ||| S:1562 E:1572 ||| NN
,  ||| S:1572 E:1574 ||| ,
while  ||| S:1574 E:1580 ||| IN
their  ||| S:1580 E:1586 ||| PRP$
phosphorylation  ||| S:1586 E:1602 ||| NN
by  ||| S:1602 E:1605 ||| IN
the  ||| S:1605 E:1609 ||| DT
activity  ||| S:1609 E:1618 ||| NN
of  ||| S:1618 E:1621 ||| IN
MAPK  ||| S:1621 E:1626 ||| NNP
pathway  ||| S:1626 E:1634 ||| FW
reduces  ||| S:1634 E:1642 ||| FW
HA  ||| S:1642 E:1645 ||| FW
synthesis ||| S:1645 E:1654 ||| FW
.  ||| S:1654 E:1656 ||| .
As  ||| S:1656 E:1659 ||| IN
the  ||| S:1659 E:1663 ||| DT
expression  ||| S:1663 E:1674 ||| NN
of  ||| S:1674 E:1677 ||| IN
the  ||| S:1677 E:1681 ||| DT
HA  ||| S:1681 E:1684 ||| NNP
receptor  ||| S:1684 E:1693 ||| NN
RHAMM  ||| S:1693 E:1699 ||| NNP
was  ||| S:1699 E:1703 ||| VBD
also  ||| S:1703 E:1708 ||| RB
significantly  ||| S:1708 E:1722 ||| RB
enhanced  ||| S:1722 E:1731 ||| VBN
by  ||| S:1731 E:1734 ||| IN
PD098059 ||| S:1734 E:1742 ||| NNP
,  ||| S:1742 E:1744 ||| ,
the  ||| S:1744 E:1748 ||| DT
MAPK  ||| S:1748 E:1753 ||| NNP
pathway  ||| S:1753 E:1761 ||| VBD
exerted  ||| S:1761 E:1769 ||| VBN
a  ||| S:1769 E:1771 ||| DT
complex  ||| S:1771 E:1779 ||| JJ
attenuating  ||| S:1779 E:1791 ||| JJ
effect  ||| S:1791 E:1798 ||| NN
on  ||| S:1798 E:1801 ||| IN
HA  ||| S:1801 E:1804 ||| NNP
signalling  ||| S:1804 E:1815 ||| NN
in  ||| S:1815 E:1818 ||| IN
the  ||| S:1818 E:1822 ||| DT
investigated  ||| S:1822 E:1835 ||| JJ
melanoma  ||| S:1835 E:1844 ||| JJ
cells ||| S:1844 E:1849 ||| NNS
.  ||| S:1849 E:1851 ||| .
This  ||| S:1851 E:1856 ||| DT
observation  ||| S:1856 E:1868 ||| NN
suggests  ||| S:1868 E:1877 ||| VBZ
that  ||| S:1877 E:1882 ||| IN
the  ||| S:1882 E:1886 ||| DT
application  ||| S:1886 E:1898 ||| NN
of  ||| S:1898 E:1901 ||| IN
MAPK-ERK  ||| S:1901 E:1910 ||| JJ
pathway  ||| S:1910 E:1918 ||| JJ
inhibitors  ||| S:1918 E:1929 ||| NN
requires  ||| S:1929 E:1938 ||| VBZ
a careful  ||| S:1938 E:1948 ||| RB
therapeutic  ||| S:1948 E:1960 ||| JJ
design  ||| S:1960 E:1967 ||| NN
in  ||| S:1967 E:1970 ||| IN
melanoma  ||| S:1970 E:1979 ||| JJ
treatment ||| S:1979 E:1988 ||| NN
.  ||| S:1988 E:1990 ||| .
